April 2nd 2025
"We must lobby to maintain our current funding levels and push for increased support to continue driving progress in cancer care," says Michael S. Cookson, MD, MMHC, FACS.
Avoidance of prostate cancer screening linked to increased risk of PCSM
March 21st 2025“Our study identifies that men who were invited for screening, but do not attend screening appointments are at significantly higher risk of dying from prostate cancer compared to men who were not offered screening or accepted an invitation for screening,” says Renée Leenen MD.
Exercise may improve erectile function in men with prostate cancer
March 17th 2025“The study suggests that exercise would be an effective intervention for men with prostate cancer who express concern about sexual dysfunction, and that exercise medicine should be considered a key part of their treatment,” says Daniel Galvão, PhD.
Michael R. Folkert, MD, PhD, discusses real-world outcomes with spacer in prostate cancer
March 17th 2025"4 years following radiation therapy, there is a 25% lower hazard of bowel disorders and a 46% lower hazard of related procedures [in patients who received a spacer],” says Michael R. Folkert, MD, PhD.
Adding ADT to SBRT improves progression-free survival in oligorecurrent HSPC
March 10th 2025"Considering that almost all patients in the combined treatment group achieved testosterone recovery at 1 year, the results support that this short term (intermittent) combined approach is an optimal option in selected patients with metachronous oligorecurrent hormone-sensitive prostate cancer," the authors wrote.
Nima Sharifi, MD, on the link between HSD3B1 and OS in prostate cancer
February 24th 2025“We hypothesized based on prior work that specifically men with low-volume disease, if they inherit this hyperactive form of HSD3B1, they'll have shorter overall survival. It turns out that that's true,” says Nima Sharifi, MD.